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Neuromyotonia is a heterogeneous group of genetic and autoimmune channelopathies resulting in hyperexcitability of peripheral
nerves. We report an unusual case of neuromyotonia, which to our knowledge has not been previously described. The patient developed
intermittent attacks of severe painful muscle stiﬀness accompanied by sweating, myokymia and raised serum creatine kinase. Genetic
analysis of KCNA1, KCNQ2 and SCN4A genes did not identify pathogenic mutation. Serum voltage-gated potassium channel antibody
was also negative. He was successfully treated with acetazolamide and carbamazepine. This appears to be a new neuromuscular disease,
“paroxysmal neuromyotonia”, the etiology of which is still unknown.
 2012 Elsevier B.V.
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Neuromyotonia is characterized by muscle stiﬀness and
cramps, myokymia, and pseudomyotonia in association
with continuous motor unit activity [1]. Most cases are
considered to be autoimmune-mediated usually related to
voltage-gated potassium channel (VGKC)-complex
antibodies [2]. Recent study demonstrated that VGKC
antibodies did not bind to Kv1 subunits but its major
target was contactin-associated protein-2 (CASPR2) [3].
CASPR2 is co-localized with Kv1.1 and 1.2 at the
juxtaparanodes in myelinated axons. It is possible that
antibodies to CASPR2 cause down-regulation of CAS-
PR2/Kv1.1/Kv1.2 complexes resulting in hyperexcitability
of peripheral nerves [3]. Although patients with a rare
inherited form often develop myokymia as a part of0960-8966 2012 Elsevier B.V.
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neuromyotonia are described [4,5]. To our knowledge, neu-
romyotonia always exhibits a chronic illness. Here, we
report clinical, electrophysiological, immunological and
genetic studies of an interesting patient with a new clinical
syndrome of paroxysmal neuromyotonia.2. Case report
A 53-year-old Thai man presented with paroxysmal
attacks of severe painful muscle stiﬀness. At age 40 years,
he experienced the ﬁrst stereotypic attack. Attacks com-
menced with a feeling of tiredness and fatigue in both legs
shortly followed by vigorous rippling muscle contraction in
both thighs and marked generalized sweating. His legs
subsequently became generally stiﬀ and painful to the point
of a stiﬀ paralysis. In a typical attack, similar symptoms
progressively aﬀected muscles in abdomen, chest, arms
and hands, but not facial muscles. The attack lasted
5–6 h. He did not observe dark urine during or after the
attacks. During the ﬁrst few years, it occurred only a few
Fig. 1. Demonstrates marked leg muscle hypertrophy.
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gradually increased. Long-periods of heavy exercise and
hot conditions induced the attacks. In contrast, rest and
cold conditions could sometimes help to ameliorate the
attacks. Four years ago, he was able to walk only a short
distance before the attack started. He developed the attack
once or twice a week with two days duration. He has no
family history of neuromuscular diseases. Treatments with
quinine, phenytoin, carbamazepine and prednisolone were
all ineﬀective. Laboratory records showed that serum
antinuclear antibody (ANA) was positive in 2007 and
2010 (peripheral pattern 1:160 and homogeneous pattern
1:160). Chest X-ray was periodically performed which
showed no evidence of thymoma or lung carcinoma.
Neurological examination four years ago was unremark-
able. However he clearly had generalized muscle hypertro-
phy despite lack of physical exercise (Fig. 1). He was
clinically diagnosed with potassium-aggravated myotonia.
250-mg of oral acetazolamide daily was prescribed. For
the next 3 years, the attacks occurred only 4 times. During
the ﬁrst week of the attacks, serum creatine kinase was
markedly increased to 1864–6482 U/L (normal 30–200
U/L) and it normalized after a month. (Table 1) He was
frequently hospitalized in attacks because of severe pain.
We observed one attack and noted the following features:
it commenced with myokymia in his thighs (VDO supple-Table 1
Shows serum creatine kinase level during and after neuromyotonia
episodes.
Weeks after
onset of each
neuromyotonia episode
Creatine kinase level (unit/litre)
02/2007 07/2007 09/2007 10/2007
0 6482 2454 1864* 2058
2 na na 481 na
3 na na na 189
4 280 366 na na
7–8 174 144* na 126
Abbreviation: na = not available.
* Blood samples were taken on consecutive days, which a regular follow-
up was on the 8th Sep 2007 and the attack was started on the 9th Sep 2007.ment 1). Half an hour later, legs were progressively stiﬀ
and he was unable to passively ﬂex his joints. His body then
became rigid and his arms and hands were subsequently
aﬀected. He had dramatic and excessive generalized sweat-
ing. At this stage myokymia became subtle. He had tachy-
cardia rate of about 100 beats per minute. We gave him
200-mg of carbamazepine. He was given intravenous 10-
mg of diazepam and 25-mg of pethidine for relieving pain.
The attack lasted for 6 h and pain had completely disap-
peared by the next morning.
About 2 years ago, he started to experience the attacks
again every 1–3 months. In view of an increased frequency
we prescribed 200-mg of carbamazepine combined with
250-mg of acetazolamide daily and since commencing this
regime he has had no further attacks, having been followed
up for 18 months.
Electromyography (EMG) was performed on gastrocne-
mius, vastus medialis and rectus femoris. Both ictal (late
phase of the attack demonstrated on VDO supplement 2)
and interictal EMG showed continuous motor unit activity
which is composed of frequent fasciculations, doublets,
triplets and runs of myokymic discharges (Fig. 2). The
motor units were of normal conﬁguration and the recruit-
ment patterns were also normal (up to 7 mV). Nerve con-
duction study was unremarkable.Fig. 2. Electromyography (interictal period) shows frequent fascicula-
tions, myokymic discharges and continuous motor unit activity.
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and SCN4A [8] genes did not identify any pathogenic
mutations. Eleven primer-pairs set for sequencing all exons
and exon–intron boundaries of KCNQ2 were newly
designed. VGKC-complex antibodies were negative by
using immunoﬂuorescent and immunoprecipitating
techniques. Other antibodies were screened including anti-
bodies to GAD, ANNA-1, ANNA-2, ANNA-3, PCA-1,
PCA-2, PCA-Tr, amphiphysin, CRMP-5, NMDA,
AMPA, GABA-b, SRP-54, which were all negative.
3. Discussion
We report a unique patient with clinical and electro-
physiological features of neuromyotonia including myoky-
mia, muscle stiﬀness and continuous motor unit activity in
association with autonomic dysfunction. Patients with clas-
sical neuromyotonia almost invariably exhibit a chronic
clinical course despite sometimes experiencing paroxysmal
painful spasms [9]. An episodic syndrome of hyperhidrosis
associated with VGKC-complex antibodies has also been
described. However that patient did not exhibit neuromus-
cular manifestations [10]. We report a unique patient with
clinical and electrophysiological features of neuromyoto-
nia. The patient was clinically similar to autoimmune neu-
romyotonia except for the paroxysmal course and
markedly distressing pain was a notable and extreme fea-
ture. Paroxysmal attacks also correlated with a striking
increase in serum creatine kinase.
During the neuromyotonia attack, muscle membrane
appeared to be severely disrupted corresponding to a
marked increase in serum creatine kinase (Table 1). This
may have also resulted in a release of myoglobin into
bloodstream causing myoglobinuria. Lack of history of
dark urine in this case may not entirely exclude the possi-
bility of dark urine, since the patient might not fully
observe color of his urine because of the distressing pain.
Laboratory testing for myoglobin level in urine is not avail-
able in Thailand, therefore we were unable to demonstrate
the existence of myoglobinuria in this patient.
Unlike acquired neuromyotonia, this patient did not
respond to monotherapy of carbamazepine and phenytoin.
But low dose of carbamazepine later showed some beneﬁt
when taken with acetazolamide. This data suggest that
the patient may have diﬀerent pathophysiological mecha-
nisms compared to classical neuromyotonia.
The etiology of neuromyotonia is usually either autoim-
mune or genetic. Acetazolamide and carbamazepine
showed a clear beneﬁt in this patient suggesting that the
primary defect might involve the function of a cellular
channel. Acetazolamide is an eﬀective treatment of inher-
ited channelopathies such as episodic ataxia and periodic
paralysis. The beneﬁt may result from its functional prop-
erties including an ability to alter cellular pH and sarcolem-
mal potassium conductance [11]. Therefore, responsiveness
to acetazolamide may not be limited to channelopathies of
inherited form. The syndrome was also late in onset, with-out a family history, and the patient repeatedly had high
ANA serum titres. However, the nature of the disease
exhibits frequent paroxysmal attacks ranging from a few
hours to every a few days since several genetic channelop-
athies exhibit an episodic nature. Autoimmune-mediated
diseases however, in association with a pathogenic
antibody, are unlikely to show disease activity which can
rise and fall in such a short period of time. So the natural
history of paroxysmal neuromyotonia suggests that a
genetic defect may be a primary underlying process.
Genetic analysis in this study does not exclude the possibil-
ities of an intronic mutation in the KCNA1, KCNQ2 or
SCN4A genes, or an unknown mutation in other genes.
In summary, we report a sporadic case of paroxysmal
neuromyotonia characterized by episodic painful muscle
stiﬀness, myokymia and excessive sweating. Acetazolamide
combined with carbamazipine appear to be eﬀective. We
did not identify antibodies to VGKC-complex and muta-
tion in SCN4A, KCNA1 and KCNQ2 genes. The pathogen-
esis of the newly described clinical syndrome is still
unknown.
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